Atria Investments’s Ligand Pharmaceuticals LGND Stock Holding History

Atria Investments’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.48M	Buy	4,667 +254	+6%	+$59.9K	0.01%	906
2026 Q1	$881K	Buy	4,413 +447	+11%	+$88.4K	0.01%	1128
2025 Q4	$750K	Sell	3,966 -1,169	-23%	-$225K	0.01%	1225
2025 Q3	$910K	Sell	5,135 -337	-6%	-$50.1K	0.01%	1100
2025 Q2	$622K	Buy	5,472 +391	+8%	+$41.8K	0.01%	1306
2025 Q1	$534K	Buy	5,081 +179	+4%	+$20.2K	0.01%	1323
2024 Q4	$525K	Buy	4,902 +217	+5%	+$24.5K	0.01%	1301
2024 Q3	$469K	Buy	4,685 +279	+6%	+$28.1K	0.01%	1364
2024 Q2	$371K	Buy	+4,406	New	+$351K	﹤0.01%	1459
2017 Q4	–	Sell	-5,277	Closed	-$448K	–	858
2017 Q3	$448K	Buy	5,277 +1,342	+34%	+$106K	0.02%	481
2017 Q2	$298K	Hold	3,935	–	–	0.02%	561
2017 Q1	$260K	Buy	3,935 +642	+19%	+$42.2K	0.02%	567
2016 Q4	$209K	Buy	+3,293	New	+$208K	0.02%	592

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Atria Investments's LGND Position: Q2 2026 in Review

Atria Investments increased its Ligand Pharmaceuticals (LGND) stake by 5.8% in Q2 2026, buying an estimated $59.9K and bringing the position to 4,667 shares worth $1.48M. The position accounts for 0.01% of the portfolio, ranked #906.

Atria Investments first reported a position in LGND in Q4 2016 and has held it in 13 quarters since. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Atria Investments held 4,667 shares of Ligand Pharmaceuticals worth $1.48M as of Q2 2026.
Atria Investments bought 254 Ligand Pharmaceuticals shares in Q2 2026, an estimated $59.9K.
Ligand Pharmaceuticals made up 0.01% of Atria Investments's portfolio in Q2 2026, its #906 holding.
Atria Investments first reported a position in Ligand Pharmaceuticals in Q4 2016 and has held it in 13 quarters since.
414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Atria Investments's 13F filing for Q2 2026, filed 28 Jul 2026.